China's ZAI Lab Ltd. has decided to return its rights to Hanmi Pharmaceutical Co. Ltd.'s novel third-generation epidermal growth factor receptor (EGFR), mutation-specific tyrosine kinase inhibitor (TKI) olmutinib (HM61713), due to a change in its new drug development strategy, said the leading South Korean pharma firm.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?